ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Friday, July 11, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Health&Beauty

Children’s asthma attacks reduced and lung function improved by Dupixent in a randomized phase 3 trial

The FINANCIAL by The FINANCIAL
October 13, 2020
in Health&Beauty
Reading Time: 3 mins read
9
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — A pivotal Phase 3 trial of Dupixent® (dupilumab) met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. In a broad type 2 inflammatory asthma patient population, defined as having elevated eosinophils (EOS) or elevated fractional exhaled nitric oxide (FeNO), Dupixent added to standard of care significantly reduced asthma attacks (exacerbations) and improved lung function, as early as two weeks after the first dose, compared to standard of care alone. More than 90% of children in the trial had at least one concurrent type 2 inflammatory condition including atopic dermatitis and eosinophilic esophagitis. Safety results from the clinical trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with moderate-to-severe asthma.

 “Children with uncontrolled moderate-to-severe asthma often struggle to breathe, largely because of their impaired lung function, and this can have a serious impact on their quality of life. It not only reduces their ability to participate in day-to-day activities, but can also take a huge emotional toll on the child and their family,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. “Dupixent is the only biologic shown in a controlled Phase 3 trial to improve lung function in children, which is generally consistent with results seen in the adolescent and adult trials. These positive data are especially encouraging for younger children who are struggling to manage their uncontrolled asthma.”

Despite standard-of-care therapy such as inhaled corticosteroids (ICS), children with uncontrolled moderate-to-severe asthma continue to experience symptoms such as coughing, wheezing, and difficulty breathing, and are at risk of severe asthma attacks.
For these children, this often leads to frequent hospitalizations and emergency room visits requiring use of systemic corticosteroids which can carry significant risks when used long-term. Uncontrolled asthma can cause children to miss school, and can interfere with physical activity and routine tasks including walking up stairs and playing sports. In the U.S., there are approximately 75,000 children 6-11 years old with uncontrolled moderate-to-severe asthma, and many more of these children worldwide.

RelatedPosts

Safety Training Seminars Review 2025- Reliable CPR and BLS Certification Courses

The power of purple glass jars and bottles for natural products

Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

“Children with moderate-to-severe asthma live with a heavy and unpredictable disease burden. Even while taking maximum treatments including inhaled corticosteroids, they suffer from multiple asthma attacks each year that may require hospitalization,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “These impressive Phase 3 data in children with asthma show Dupixent significantly reduced annual severe asthma attacks and also improved lung function consistently across patients with markers of type 2 inflammation.”

See also  Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

The primary endpoint assessed the annualized rate of severe asthma attacks in two primary pre-specified populations: patients with baseline blood EOS ≥300 cells/μl and patients with markers of type 2 inflammation (FeNO ≥20 ppb or EOS ≥150 cells/μl). Across these two patient groups respectively, those who added Dupixent (100 mg or 200 mg every two weeks, based on weight) to standard of care experienced:

  • Reduced rate of severe asthma attacks, with a 65% (p<0.0001) and 59% (p<0.0001) average reduction over one year compared to placebo (0.24 and 0.31 events per year for Dupixent vs. 0.67 and 0.75 for placebo, respectively)
  • Improved lung function at 12 weeks compared to baseline by 10.15 and 10.53 percentage points for Dupixent vs. 4.83 and 5.32 percentage points for placebo (least squares mean difference for Dupixent vs. placebo of 5.3 and 5.2 percentage points, p=0.0036 and p=0.0009), respectively, as measured by percent predicted FEV1 (FEV1pp). FEV1pp is a common endpoint in pediatric asthma trials to evaluate a patient’s change in lung function compared to their predicted lung function based on a number of factors including age, height and sex, to account for children’s growing lung capacity at different stages of development. This clinically meaningful improvement in lung function was observed as early as two weeks and was sustained for up to 52 weeks.

The safety results from the trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with moderate-to-severe asthma. Over one year, overall rates of adverse events were 83% for Dupixent and 80% for placebo. Adverse events that were most commonly observed with Dupixent versus placebo included injection site reactions (18% for Dupixent and 13% for placebo), viral upper respiratory tract infections (12% for Dupixent and 10% for placebo), and eosinophilia (6% for Dupixent and 1% for placebo).  

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), atopic dermatitis and eosinophilic esophagitis.

Tags: asthmaasthma attacksasthma in childrendupilumabdupilumab phase 3Dupixentsanof

Related Posts

Safety Training Seminars Review 2025- Reliable CPR and BLS Certification Courses
Education

Safety Training Seminars Review 2025- Reliable CPR and BLS Certification Courses

by The FINANCIAL
July 5, 2025
0

When it comes to workplace safety and emergency preparedness, you must have proper training. Safety Training Seminars give you a...

Read more
The power of purple glass jars and bottles for natural products

The power of purple glass jars and bottles for natural products

June 28, 2025
Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

June 24, 2025
Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

June 11, 2025

Discussion about this post

  • Trending
  • Comments
  • Latest
Spot Hbar ETF Odds Increase to 90% as Institutions Bet Big on Hedera

Spot Hbar ETF Odds Increase to 90% as Institutions Bet Big on Hedera

July 3, 2025
Teaching porn literacy

A sizable percentage of internet porn users, roughly 40% are women

January 17, 2024
2025 Review Of NEXT New Growth | Executive Coaching For CFOs

2025 Review Of NEXT New Growth | Executive Coaching For CFOs

July 4, 2025
SCOPE Recruiting: Honest Review For 2025

SCOPE Recruiting: Honest Review For 2025

July 3, 2025
On U.S. Independence Day Russia Launched One of Its Largest Air Attacks of the Full-scale War

On U.S. Independence Day Russia Launched One of Its Largest Air Attacks of the Full-scale War

July 4, 2025
Most Americans continue to say media scrutiny keeps politicians from doing things they shouldn’t

Dramatic rise in the number of journalists killed in six months



July 11, 2025
Euro area international trade in goods surplus €7.3 bn

Trade talks EU–US: Trade in services should be taken into account

July 11, 2025
Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

July 11, 2025
Update by The Florida Department of Transportation: Key Improvements

Update by The Florida Department of Transportation: Key Improvements

July 11, 2025
Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

July 11, 2025
ADVERTISEMENT

Popular Last 24h

  • Teaching porn literacy

    A sizable percentage of internet porn users, roughly 40% are women

    748 shares
    Share 299 Tweet 187
  • Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

    18 shares
    Share 7 Tweet 5
  • Ampersand wins £22m five-year contract at London Zoo

    4041 shares
    Share 1616 Tweet 1010
  • Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

    17 shares
    Share 7 Tweet 4
  • Teaching porn literacy

    324 shares
    Share 130 Tweet 81
  • Trade talks EU–US: Trade in services should be taken into account

    16 shares
    Share 6 Tweet 4
  • Dramatic rise in the number of journalists killed in six months



    14 shares
    Share 6 Tweet 4

LATEST POSTS

Most Americans continue to say media scrutiny keeps politicians from doing things they shouldn’t

Dramatic rise in the number of journalists killed in six months



July 11, 2025
Euro area international trade in goods surplus €7.3 bn

Trade talks EU–US: Trade in services should be taken into account

July 11, 2025
Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

July 11, 2025
Update by The Florida Department of Transportation: Key Improvements

Update by The Florida Department of Transportation: Key Improvements

July 11, 2025
Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

July 11, 2025
Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

July 9, 2025
10 Ways to Master Your Personal Finances

10 Ways to Master Your Personal Finances

July 9, 2025

0xea699498

July 9, 2025
wall_street_sign.jpg

Wall Street Giants Now Worth $59.7 Trillion, More Than the GDP of the U.S., China, and Germany Combined

July 9, 2025
OCCRP Exclusive: Top Trump Adviser Sergio Gor Was Born in the Soviet Union

OCCRP Exclusive: Top Trump Adviser Sergio Gor Was Born in the Soviet Union

July 8, 2025

LATESTBUSINESS

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

Private Equity Giant H.I.G. Capital Nets Strong Returns on Jewelry Brand While Betting Big on Canadian Fuel Services

by The FINANCIAL
July 11, 2025
0

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

Smart Storage: Creative Ways Mini-Storage Buildings Are Meeting Modern Needs

by The FINANCIAL
July 11, 2025
0

Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

Moldova’s Virtual IT Park Attracts Global Attention with Record Growth and €1 Billion Revenue Target

by The FINANCIAL
July 9, 2025
0

wall_street_sign.jpg

Wall Street Giants Now Worth $59.7 Trillion, More Than the GDP of the U.S., China, and Germany Combined

by The FINANCIAL
July 9, 2025
0

Are You Really Targeting the Right Customer

Are You Really Targeting the Right Customer

by The FINANCIAL
July 8, 2025
0

Prominent Georgian Businessman Behind Euronews and National Geographic Arrested in Tbilisi

Prominent Georgian Businessman Behind Euronews and National Geographic Arrested in Tbilisi

by The FINANCIAL
July 7, 2025
0

Etisalat and Ericsson trial Massive MIMO technology in the UAE

Global study shows 96% plan to increase yield focus in anticipation of market correction

by The FINANCIAL
July 7, 2025
0

How Responsible Money Management Can Improve Your Financial Well-being

AnaIysis Reveals Significant Focus on Private Assets by Insurers Using External Investment Managers 

by The FINANCIAL
July 7, 2025
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+995 558) 03 03 03 Email: marketing (at) finchannel.com

Whatsup: (+995 599) 96 52 52

Georgia:

(+995 599) 96 52 52 Email: editor (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.